Navelbine® (Vinorelbine Tartrate)

Navelbine:

Facts of Navelbine ®(Vinorelbine Tartrate) ?

  • Medicine Name: Navelbine®
  • Generic Name: Vinorelbine Tartrate
  • Approval Date: 6/8/2000
  • Company Name: GlaxoSmithKline.
  • Available as (Form & Strength): Injection: 40 mg/4 mL and 100 mg/10 mL solution in a single-use vial.

What are the indications and usage?

NAVELBINE is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with Stage IV NSCLC, NAVELBINE is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, NAVELBINE is indicated in combination with cisplatin